At the time, the drugmaker said it based the determination on the deceptive promotion and selling of illegitimate knockoff versions that put patient safety at risk. This week, Novo Nordisk described Hims & Hers compounded semaglutide weight loss pill as another example of the companys historic behaviour of duping the American public with knock-off GLP-1 products. Semaglutide is the active ingredient in GLP-1 drugs
Because retatrutide is still investigational, access currently requires enrollment in a clinical trial or, in some markets, a compounding pharmacy prescription under off-label frameworks
246 , 193199 (1997) Mller, A., Ulm, H., Reder-Christ, K., Sahl, H
10.1152/physrev.00019.2003